OFIX at a glance
Orthofix Medical Inc. (OFIX, SEC CIK 884624) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and Form 4 insider filings as recently as October 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Orthofix Medical Inc. (OFIX) reported revenue of $822.3 million (up 2.9% from FY2024) and a net loss of $92.2 million. Diluted EPS was -$2.33.
- As of June 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Orthofix Medical Inc. (OFIX) shares worth $103.8 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Fisher Patrick on October 1, 2026 of 150 shares at $9.44 per share.
- In the last 90 days, OFIX insiders reported 2 open-market purchases ($2.7M) and 7 open-market sales ($3.2M) on Form 4, a net sale of $419K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $822.3M
- +2.9% vs prior year
- Insiders · 90 days
- 2 buys · 7 sells
- Net −$419K
- 13F holders
- 25 funds
- $103.8M · +2 vs prior quarter
- Latest 8-K
- Aug 5, 2026
- Item 7.01 · Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- No risk-factors section provided; supplied text contains Items 2–6 only
- No newly added or materially updated risks identifiable from the provided excerpt
- Executive trading-plan disclosure: up to 1,800 shares through August 31, 2027
- No regulatory, legal, operational, competitive, market, liquidity, debt, currency, or concentration risks disclosed
AI summary of the OFIX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Investor-relations presentation authorized for use through December 31, 2026
- Exhibit 99.2 may support presentations to investors, analysts, and other stakeholders
Item EX-99.1: Item EX-99.1
- Q2 net sales $210.9M, up 3.8% reported and 4.7% pro forma constant currency, supporting improved operating momentum
- Global Limb Reconstruction grew 13.2%, while Global Spine increased 3.5% pro forma, offsetting weaker portfolio areas
Item 2.02: Results of Operations and Financial Condition
- Management emphasizes adjusted EBITDA as its primary operating metric, alongside adjusted earnings, margins, expenses, and free cash flow
- Exclusions include SeaSpine merger costs, M6 product-line losses, restructuring, litigation, acquisitions, and employee transitions
Item 7.01: Regulation FD Disclosure
- CMS withdrew reimbursement changes for non-invasive bone growth stimulators effective May 18, 2026
- Medicare billing for HCPCS codes E0747, E0748 and E0760 returns to pre-reclassification treatment
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Shareholders approved Amendment No. 5 to Orthofix’s stock purchase plan on June 10, 2026
- Share reserve increased by 1,250,000 common shares for employee purchases
Item 5.07: Submission of Matters to a Vote of Security Holders
- 34,776,676 shares represented, exceeding the 20,192,935-share quorum requirement
- All 10 director nominees elected for one-year terms expiring at the 2027 annual meeting
AI summaries of OFIX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for OFIX
Don't miss the next OFIX filing
- Alerts as it files. A push when OFIX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut OFIX, by share count.
- Ask anything. An AI agent that reads every OFIX filing and answers with sources.
OFIX alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Fisher Patrick | Sell | Oct 1, 2026 | 150 | $9.44 |
| Juniper Investment Company, LLC | Sell | Sep 21, 2026 | 190,000 | $8.86 |
| Juniper Investment Company, LLC | Buy | Sep 21, 2026 | 190,000 | $8.86 |
| Juniper Investment Company, LLC | Buy | Sep 18, 2026 | 120,000 | $8.74 |
| Juniper Investment Company, LLC | Sell | Sep 18, 2026 | 120,000 | $8.74 |
| Fisher Patrick | Sell | Sep 1, 2026 | 150 | $9.39 |
| Fisher Patrick | Sell | Aug 18, 2026 | 1,295 | $10.09 |
| Juniper Investment Company, LLC | Sell | Aug 17, 2026 | 20,000 | $10.01 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $746.6M | $799.5M | $822.3M |
| Gross Profit | - | $545.9M | $566.0M |
| Operating Income | - | -$84.6M | -$81.4M |
| Net Income | - | -$126.0M | -$92.2M |
| Gross Margin | - | 68.3% | 68.8% |
| Op. Margin | - | -10.6% | -9.9% |
| Net Margin | - | -15.8% | -11.2% |
| Balance Sheet | |||
| Total Assets | $925.3M | $893.3M | $850.6M |
| Equity | $598.7M | $503.1M | $450.0M |
| ROE | - | -25.0% | -20.5% |
| Per Share | |||
| EPS | - | $-3.30 | $-2.33 |
| Cash Flow | |||
| Operating CF | - | $25.8M | $33.3M |
| CapEx | $60.3M | - | - |
Source: XBRL data in Orthofix Medical Inc. (OFIX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate OFIX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 25 | $103.8M |
| Q1 2026 | 23 | $117.2M |
| Q4 2025 | 23 | $160.0M |
| Q3 2025 | 25 | $163.7M |
| Q2 2025 | 26 | $124.0M |
| Q1 2025 | 21 | $89.4M |
| Q4 2024 | 17 | $83.5M |
| Q3 2024 | 15 | $40.1M |
- AQR Capital Management+698.2K (+369%)
- FMR LLC (Fidelity)+170.7K (+180%)
- Goldman Sachs Group+121.7K (+38%)
- BlackRock+118.8K (+4%)
- Morgan Stanley+98.3K (+50%)
- Millennium Management−204.9K (-19%)
- Dimensional Fund Advisors−109.9K (-13%)
- Citadel Advisors LLC−77.0K (-61%)
- JPMorgan Chase & Co−25.5K (-13%)
- Renaissance Technologies LLC−5.2K (-5%)
- D.E. Shaw & Co+11.4K
- Two Sigma Investments+10.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 175 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
OFIX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Sep 23, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 8-K | Jul 2, 2026 | - | Analysis | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 8-K | Jun 11, 2026 | - | Analysis | - |
| 4 | May 29, 2026 | - | - | |
| 8-K | May 21, 2026 | - | Analysis | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 7, 2026 | - | - | |
| 10-Q | May 5, 2026 | Mar 31, 2026 | Analysis |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
OFIX SEC filings: frequently asked questions
Are OFIX insiders buying or selling?
In the last 90 days, Orthofix Medical Inc. (OFIX) officers, directors and 10% owners reported 2 open-market purchases worth $2.7 million by 1 insider and 7 open-market sales worth $3.2 million by 2 insiders on Form 4, a net sale of $418,635. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold OFIX stock?
As of June 30, 2026, the largest Orthofix Medical Inc. (OFIX) holders among the 13F filers tracked by SignalX were BlackRock ($30.4 million), Vanguard Capital Management LLC ($15.8 million), State Street Corp ($8.7 million), AQR Capital Management ($8.1 million), Millennium Management ($7.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was OFIX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Orthofix Medical Inc. (OFIX) reported revenue of $822.3 million (up 2.9% from FY2024) and a net loss of $92.2 million. Diluted EPS was -$2.33. The figures come from the XBRL data in the 10-K.
What did OFIX report in its latest 8-K?
Orthofix Medical Inc. (OFIX) filed an 8-K on August 5, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 2.02 (Results of Operations and Financial Condition). Investor-relations presentation authorized for use through December 31, 2026.
What are the latest OFIX SEC filings?
Orthofix Medical Inc. (OFIX) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and a Form 4 insider filing on October 5, 2026.
What is OFIX's SEC CIK number?
Orthofix Medical Inc. (OFIX)'s SEC Central Index Key (CIK) is 884624. EDGAR lists every OFIX filing under that number.
Ask anything about OFIX
The research agent reads OFIX's filings, financials, insider trades and 13F holders, then answers with sources.